

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Watowich et al.)	Group Art Unit:	1632
)		
Serial No.: 09/981,286)	Examiner:	Unknown
Confirmation No.: 4993)		
)		
Filed: October 15, 2001)		
)		
For: DRUG DISCOVERY METHODS)		

REQUEST FOR CORRECTED FILING RECEIPT

Assistant Commissioner for Patents
Attn: Box Missing Parts
Washington, D.C. 20231

Sir:

Upon review of the Filing Receipt received from the U.S. Patent and Trademark Office in connection with the above-identified application, the following error was noted.

Specifically, the total number of independent claims filed in this application is 15, not 9. A copy of the Filing Receipt with this correction marked in red is enclosed. Applicants respectfully request a corrected Filing Receipt.

If the Examiner has any questions regarding this submission, please contact Applicants' Representative at the below-listed telephone number.


Respectfully submitted,

Watowich et al.


By
Muetting, Raasch & Gebhardt, P.A.
P.O. Box 581415
Minneapolis, MN 55458-1415
Telephone: (612) 305-1220
Facsimile: (612) 305-1228

CERTIFICATE UNDER 37 C.F.R. 1.8:

The undersigned hereby certifies that this paper is being deposited in the United States Postal Service, as first class mail, in an envelope addressed to: Assistant Commissioner for Patents, ATTN: MISSING PARTS, Washington, D.C. 20231, on this 28th day of January, 2002.


David L. Provence

January 28, 2002
Date

By: 
David L. Provence
Reg. No. 43,022
Direct Dial (612) 305-1005



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/981,286	10/15/2001	1632	0.00	265.0026 0101	5	34	X 15

CONFIRMATION NO. 4993

26813
MUETING, RAASCH & GEBHARDT, P.A.
P.O. BOX 581415
MINNEAPOLIS, MN 55458

FILING RECEIPT



OC00000007121783

Date Mailed: 11/27/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Stanley J. Watowich, Houston, TX;
Scott C. Weaver, Galveston, TX;
Robert A. Davey, Galveston, TX;

Assignment For Published Patent Application

Board of Regents, The University of Texas System, Austin, TX;

Domestic Priority data as claimed by applicant

THIS APPLN CLAIMS BENEFIT OF 60/240,187 10/13/2000

Foreign Applications

If Required, Foreign Filing License Granted 11/26/2001

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title

Drug discovery methods

Preliminary Class

435

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).